Project profile — Ancillary costs for donated COVID-19 vaccine doses procured via the COVAX Facility

• Africa, regional (50.00%)
• America, regional (20.00%)
• Asia, regional (25.00%)
• Oceania, regional (2.00%)
• Europe, regional (3.00%)

• Health: COVID-19 control (12264) (100.00%)

• Gender equality (significant objective)
• Environmental sustainability (cross-cutting) (not targeted)
• Participatory development and good governance (not targeted)
• Trade development (not targeted)
• Biodiversity (not targeted)
• Climate change mitigation (not targeted)
• Climate Change Adaptation (not targeted)
• Urban issues (not targeted)
• Desertification (not targeted)
• Children's issues (not targeted)
• Youth Issues (not targeted)
• Disaster Risk Reduction(DRR) (not targeted)
• Indigenous Issues (not targeted)
• Disability (not targeted)
• Nutrition (significant objective)
• ICT as a tool for development (not targeted)

This project aims to decrease COVID-19 related mortality and morbidity, especially for those experiencing marginalization or vulnerability, including women. The project also seeks to provide sufficient vaccine doses to immunize healthcare workers and most vulnerable groups in low- and lower-middle income countries. Project activity includes providing the necessary ancillaries to accompany COVID-19 vaccines declared surplus and donated by Canada to the COVAX Facility. Ancillaries may include freight, equipment, No Fault Compensation Scheme contribution, safety boxes, and syringes.

The expected outcomes of this project include: (1) decreased COVID-19 related mortality and morbidity of priority populations, especially for those experiencing marginalization or vulnerability, including women; and (2) increased vaccine doses to support immunization of healthcare workers and most vulnerable groups in low- and lower-middle-income countries.

N/A

• Proactive disclosure